Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10637-009-9261-5.pdf
Reference37 articles.
1. Pavlidis N (2007) Forty years experience of treating cancer of unknown primary. Acta Oncol (Madr) 46:592–601. doi: 10.1080/02841860701243095
2. Varadhachary GR, Talantov D, Raber MV, Meng C, Hess KR, Jatkoe T et al (2008) Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26:4442–4448. doi: 10.1200/JCO.2007.14.4378
3. Harlings HM, Van Laar RK, Kerst JM, Helgasar HM, Wessling J, Van der Hoeven JJ et al (2008) Gene expression profiling to identify the histogenetic origin of metastases adenocarcinoma of unknown primary. J Clin Oncol 26:4435–4441. doi: 10.1200/JCO.2007.14.6969
4. Culine S, Lhortolary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminisky MC et al (2003) Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French study group on carcinomas of unknown primary (GEFCAPI 01). J Clin Oncol 21:3479–3482. doi: 10.1200/JCO.2003.12.104
5. Palmeri S, Lorusso V, Palmeri L, Vaglica M, Porta C, Nortilli R et al (2006) Cisplatin and gemcitabine with either vinorelebine or paclitaxel in the treatment of carcinomas of unknown primary. Cancer 107:2898–2905. doi: 10.1002/cncr.22379
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinicopathological, molecular and prognostic characteristics of cancer of unknown primary in China: An analysis of 1420 cases;Cancer Medicine;2022-07-13
2. Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012;European Journal of Cancer;2018-09
3. Docetaxel and Cisplatin in First Line Treatment of Patients with Unknown Primary Cancer: A Multicenter Study of the Anatolian Society of Medical Oncology;Asian Pacific Journal of Cancer Prevention;2014-02-28
4. Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis;British Journal of Cancer;2012-11-22
5. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial;European Journal of Cancer;2012-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3